News articles about Lion Biotechnologies (NASDAQ:IOVA) have trended somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lion Biotechnologies earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.7685406456812 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s analysis:
- Lion Biotechnologies, Inc. (IOVA) Earns “Buy” Rating from HC Wainwright (americanbankingnews.com)
- Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target at Oppenheimer Holdings, Inc. (americanbankingnews.com)
- Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management (finance.yahoo.com)
- Head-To-Head Review: Digiliti Money (DGLT) vs. Lion Biotechnologies (IOVA) (americanbankingnews.com)
- Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center (finance.yahoo.com)
IOVA has been the topic of several recent research reports. Jefferies Group LLC restated a “buy” rating and issued a $11.00 target price on shares of Lion Biotechnologies in a report on Thursday, May 18th. FBR & Co restated a “buy” rating on shares of Lion Biotechnologies in a report on Thursday, May 18th. Chardan Capital restated a “buy” rating on shares of Lion Biotechnologies in a report on Wednesday, May 17th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a report on Saturday, May 20th. Finally, Zacks Investment Research upgraded shares of Lion Biotechnologies from a “sell” rating to a “hold” rating in a report on Tuesday, May 23rd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $13.88.
Shares of Lion Biotechnologies (NASDAQ:IOVA) traded up 2.76% during mid-day trading on Wednesday, reaching $7.45. 467,480 shares of the company were exchanged. Lion Biotechnologies has a 12 month low of $4.45 and a 12 month high of $8.61. The firm’s market capitalization is $467.02 million. The company’s 50-day moving average is $5.61 and its 200 day moving average is $6.42.
COPYRIGHT VIOLATION WARNING: This article was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/09/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-lion-biotechnologies-iova-share-price.html.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.